A
RLM

Abingworth’s Realm Therapeutics plc American Depositary Shares RLM Stock Holding History

Abingworth’s Portfolio RLM Stock Details RLM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-255,371
Closed -$988K – 15
2019
Q1 		$988K Buy
+255,371
New +$716K 0.88% 13

Other funds holding RLM

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $102M AUM 0.13% 1-Year Est. Return

Abingworth's RLM Position: Q2 2019 in Review

Abingworth sold out of Realm Therapeutics plc American Depositary Shares (RLM) in Q2 2019, closing a stake of 255,371 shares — an estimated $988K sold.

Abingworth first reported a position in RLM in Q1 2019 and held it in 1 quarter. The position peaked at $988K in Q1 2019. 7 funds tracked by Wall St. Rank hold RLM as of Q2 2019.

  • Abingworth reported no remaining Realm Therapeutics plc American Depositary Shares position as of Q2 2019 after selling out during the quarter.
  • Abingworth sold 255,371 Realm Therapeutics plc American Depositary Shares shares in Q2 2019, an estimated $988K.
  • Abingworth first reported a position in Realm Therapeutics plc American Depositary Shares in Q1 2019 and held it in 1 quarter.
  • Abingworth's Realm Therapeutics plc American Depositary Shares position peaked at $988K in Q1 2019.
  • 7 funds tracked by Wall St. Rank held Realm Therapeutics plc American Depositary Shares as of Q2 2019.

Based on Abingworth's 13F filing for Q2 2019, filed 14 Aug 2019.